Fluidigm said this week that Un Kwon-Casado has been promoted to the position of vice president of corporate development.
Kwon-Casado has served as director of strategic marketing at Fluidigm since October 2009. Prior to that she was vice president of healthcare equity research for Pacific Growth Equities.
Howard High, a fellow and investor relations officer at Fluidigm, had previously been handling the company's investor relations, and will continue on as the company's public relations representative, Fluidigm CEO Gajus Worthington said this week during the company's third-quarter earnings call.
Epigenomics disclosed last week that Thomas Taapken has been appointed as sole member of the company's executive board, effective Oct. 1. Previous Epigenomics CEO Geert Nygaard retired from the company effective Sept. 30.
Taapken previously served as CFO at Epigenomics, a position he held since April 2011. He joined Epigenomics from Biotie Therapies in Finland, where he also served as CFO. He was appointed to this position in 2008, following a merger between Biotie Therapies and Elbion, where Taapken had been CFO since 2005. He has also held positions as an investment partner at Deutsche Venture Capital and Burrill & Company. Taapken also worked several years at Sanofi-Aventis.
Epigenomics also disclosed that it has promoted Uwe Staub, former senior vice president of research and development, to the position of COO.